Maxwell Biosciences

Executive Summary

Maxwell Biosciences is a preclinical-stage biotechnology company pioneering a novel class of broad-spectrum anti-infective therapeutics using its proprietary Claromer® platform. The platform designs peptidomimetic small molecules that mimic the body's innate immune peptides, targeting bacteria, fungi, and viruses without inducing resistance. This approach addresses the critical global threat of antimicrobial resistance and provides a potential defense against future pandemics. The company's lead compounds have shown promising in vitro activity against multidrug-resistant pathogens. With a focus on age-related immune decline and pandemic preparedness, Maxwell aims to develop a pathogen-agnostic biodefense shield. While still in early preclinical development, the platform's versatility and novel mechanism of action position it as a potential breakthrough in infectious disease treatment.

Upcoming Catalysts (preview)

• Q4 2026Release of in vivo efficacy data for lead compound in animal models60% success
• Q1 2027Completion of IND-enabling toxicology studies50% success
• Q2 2027Series A financing or strategic partnership announcement70% success